This post was originally published on this site The expansion part of a Phase 1/2 clinical trial testing tinostamustine in relapsed or refractory blood cancers has begun treating the first patient. The trial (NCT02576496), conducted by Mundipharma EDO in collaboration with Imbrium Therapeutics, is currently seeking about 111 adult patients in the U.S. and Europe with either…
This post was originally published on this site Fatigue is the most commonly reported symptom by sarcoidosis patients in Denmark, Germany, and the Netherlands, according to a survey conducted by researchers from those countries. Nerve damage-related symptoms are a close second. The study, “The Burden of Sarcoidosis Symptoms from a Patient Perspective” was published in…
This post was originally published on this site Estradiol, a type of estrogen and the major female hormone, may drive the spread of cancer to the brain in women with triple-negative breast cancer (TNBC), a study in mice and human cells reports. Researchers identified a chain of molecular events triggered by estradiol that appears to…
This post was originally published on this site A reduced number of lymphocytes — one of the main types of immune cells — in advanced ovarian cancer patients before treatment is linked with a higher risk of disease worsening and shorter overall survival, according to a South Korean study. The study, “Pretreatment lymphocytopenia is an…
This post was originally published on this site A triple combination of Darzalex (daratumumab), Velcade (bortezomib), and dexamethasone will be available on the National Health Service (NHS) in England for the treatment of relapsed or refractory multiple myeloma patients. The U.K.’s National Institute of Health and Care Excellence (NICE) decided to approve the therapy based on…
This post was originally published on this site Scotland’s healthcare system has rejected the use of Novartis‘ immunotherapy Kymriah (tisagenlecleucel) for adults with aggressive diffuse large B-cell lymphoma (DLBCL) who failed at least two prior lines of therapy. The Scottish Medicines Consortium (SMC) denied routine access to Kymriah through NHS Scotland based on “uncertainties in the company’s evidence around its…
This post was originally published on this site The U.S. Food and Drug Administration has approved the use of Tecentriq (atezolizumab) in combination with the chemotherapies Paraplatin (carboplatin) and etoposar for the initial treatment of extensive-stage small-cell lung cancer patients. The approval, which makes Tecentriq the first immunotherapy approved for this indication, is based on findings…
This post was originally published on this site An artificial intelligence (AI) system based on deep learning algorithms is able to detect breast cancer in digital mammography screenings as well as experienced radiologists, a study says. The findings of the study, “Stand-Alone Artificial Intelligence for Breast Cancer Detection in Mammography: Comparison With 101 Radiologists,” were…
This post was originally published on this site An inaugural effort by the Atlanta Hawks to help defeat prostate cancer by raising awareness and funds for important research netted $150,000 for the Prostate Cancer Foundation (PCF). The NBA basketball team’s drive was launched in February during African-American History Month to bring greater awareness of the disorder to…
This post was originally published on this site Children, adolescents, and young adults with relapsed or refractory cancers — particularly those with lymphoma — have better responses to Genentech‘s immune checkpoint inhibitor Tecentriq (atezolizumab) if they have high levels of the PD-L1 factor in their tumors, a study found. The findings will be presented during…
